Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
336 Results for "
MRSA
" in MedChemExpress (MCE) Product Catalog:
Products (336)
336 Results for "MRSA" in MCE Product Catalog:
Cat. No.: HY-143326
CAS No.: 2413865-92-4
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
Cat. No.: HY-14737R
CAS No.: 400827-46-5
Synonyms: TAK-599 (Standard); PPI0903 (Standard)
Target:
Research Areas:
Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].
Cat. No.: HY-173478
CAS No.: 3053515-60-6
Target:
Research Areas:
OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
Cat. No.: HY-P5706
Target:
Research Areas:
Target:
Research Areas:
HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .
Cat. No.: HY-173225
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .
Cat. No.: HY-179059
Research Areas:
Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections .
Cat. No.: HY-168705
Anti-MRSA agent 20 (Compound a4) is an anti-microbial agent (MIC: < 0.03125 μg/mL) against MRSA). Anti-MRSA agent 20 binds to the ribosomal peptidyl transferase center and inhibits bacterial survival by inhibiting MRSA toxin synthesis and bacterial division. Anti-MRSA agent 20 significantly reduces the MRSA load in the lungs and attenuates lung injury in the MRSA-infected mice (ED50 = 6.48 mg/kg) .
Cat. No.: HY-161827
CAS No.: 3050586-22-3
Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively .
Cat. No.: HY-144278
CAS No.: 2627336-02-9
Target:
Research Areas:
Anti-MRSA agent 1 (Compound 13d) is a wonderful MRSA (MIC = 0.5 μg/mL) inhibitor. Anti-MRSA agent 1 (Compound 13d) could effectually relieve the development of MRSA resistance .
Cat. No.: HY-163906
CAS No.: 3057628-14-2
Anti-MRSA agent 16 (Compound 4) is an inhibitor of methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 16 is effective in combination with oxacillin or meropenem in infected mice .
Anti-MRSA agent 8 (Compound 7g) is a DAPG derivative with strong antibacterial activity. Anti-MRSA agent 8 assertes its activity by targeting bacterial cell membranes. Anti-MRSA agent 8 can be used for the research of methicillin-resistant Staphylococcus aureus (MRSA) .
Cat. No.: HY-178493
CAS No.: 3064702-33-3
Anti-MRSA agent 37 (Compound 5B) is an antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) (MIC=0.25-0.5 μg/mL). Anti-MRSA agent 37 inhibits biofilm formation, disrupts cell wall integrit, attacks cell membrane and induces oxidative stress. Anti-MRSA agent 37 is promising for research of MRSA-related diseases such as skin infections .
Cat. No.: HY-161893
Anti-MRSA agent 15 (Compound 9o10) exhibits antibacterial activity, that inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.0625 μg/mL. Anti-MRSA agent 15 exhibits low hemolysis and low cytotoxicity. Anti-MRSA agent 15 exhibits anti-infective in mice .
Cat. No.: HY-168873
CAS No.: 2607085-75-4
Anti-MRSA agent 23 (compound 11) is a potent anti-methicillin-resistant Staphylococcus aureus agent. Anti-MRSA agent 23 shows antibacterial and antibiofilm activities. Anti-MRSA agent 23 accelerates the reconstruction and healing of MRSA-infected cutaneous wounds by decreasing bacterial loads, attenuating inflammation, and promoting angiogenesis .
Cat. No.: HY-161823
Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies .
Cat. No.: HY-178108
Research Areas:
Anti-MRSA agent 35 (Compound 6b) is an anti-MRSA agent. Anti-MRSA agent 35 significantly inhibits MRSA biofilm formation, suppresses penicillin-binding protein (PBP2a) expression and induces mecA virulence gene mutation. Anti-MRSA agent 35 has potent bactericidal and fungicidal activities with MIC50s of 7.8-31.25 μg/mL for gram positive bacteria, gram-negative bacteria and Fungi. .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
